Eligard 7.5 mg/ 22.5 mg/ 30 mg/ 45 mg Implants in pre-filled syringes.
PDF Leaflet Revision Date: 23 July 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Palliative treatment of advanced prostate cancer.
Dosage (summary)
7.5 mg monthly, 22.5 mg every 3 months, 45 mg every 6 months.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; can cause fetal harm.
Key Drug Interactions
- QT prolonging agents
- GnRH agonists
Contraindications
- Hypersensitivity to leuprorelin
- Pregnancy
- Lactation
- Women and pediatric patients
Common side effects
- Hot flushes
- Fatigue
- Dizziness
- Injection site reactions
Counselling Points
- Monitor for signs of testosterone flare
- Report severe skin reactions
- Avoid in pregnancy and breastfeeding
Serious warnings
- Transient testosterone flare
- Risk of hyperglycemia
- Cardiovascular risks
- Severe skin reactions
Important Disclaimer
The Eligard 7.5 mg/ 22.5 mg/ 30 mg/ 45 mg Implants in pre-filled syringes. professional information leaflet below is the property of Key Oncologics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
